Trial Profile

A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women With Hormone Receptor Positive Breast Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 22 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vosilasarm (Primary)
Indications Advanced breast cancer
Focus Adverse reactions; First in man
Sponsors Radius Health Inc.

Most Recent Events

15 Oct 2020 Status changed from active, no longer recruiting to completed.
14 Dec 2019 Results determining maximum tolerated dose and recommended dose for RAD140 were presented at the 42nd Annual San Antonio Breast Cancer Symposium
06 Dec 2019 According to a Radius Health media release, data from this study will be presented at the upcoming 2019 San Antonio Breast Cancer Symposium, on December 13 in San Antonio, Texas

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com